Straits Times Index
3,314.05 +0.57 (+0.02%) S&P 500
5,321.20 +17.93 (+0.34%) Dow
39,978.07 -25.52 (-0.06%) Nasdaq
16,818.10 +132.13 (+0.79%) Bitcoin USD
68,194.54 +1,442.00 (+2.16%) CMC Crypto 200
1,380.11 +25.69 (+1.90%)
ROIV May 2024 10.000 call
| Previous close | 1.2700 |
| Open | 1.0200 |
| Bid | 0.3500 |
| Ask | 2.3000 |
| Strike | 10.00 |
| Expiry date | 2024-05-17 |
| Day's range | 1.0200 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.75k |
GlobeNewswireRoivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
BASEL, Switzerland and LONDON and NEW YORK, May 16, 2024 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, May 30, 2024, to report its financial results for the fourth quarter and fiscal year ended March 31, 2024, and provide a business update. To access the conference call by phone, please register online using this registration link. The presentation and webcast details will also be available under “Even
Simply Wall St.Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain
Key Insights Significantly high institutional ownership implies Roivant Sciences' stock price is sensitive to their...
- GlobeNewswire
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Roivant’s board of directors has approved a share repurchase program for up to $1.5 billion of the company’s common shares, including an agreed repurchase of the entire Sumitomo Pharma stake for $648 millionSumitomo Pharma repurchase reduces shares outstanding by 9%In the Phase 2 NEPTUNE study of once-daily oral brepocitinib in non-infectious uveitis (NIU), the 45 mg results represent the best Treatment Failure rates observed to date among active NIU studies measuring this registrational endpoin
